ACADIA Pharmaceuticals Inc. vs Vanguard S&P 500 ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.54 (market cap $5.07B), while Vanguard S&P 500 ETF trades at $710.95. Which is the better fit depends on your goals.
| ACAD | VOO | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.41 | $710.71 |
52-Week Low | $20.06 | $580.93 |
Enterprise Value | $4.19B | — |
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
VOO trades at $710.69 with minimal daily movement (+0.01%), maintaining a bullish technical stance as the S&P 500 ETF approaches record highs. The overall technical signal is bullish with strong moving average support, though oscillators show neutral momentum. Recent news highlights the S&P 500's elevated valuation levels while institutional interest remains strong, with Bay Colony Advisory increasing its position by 8.6% in Q2 2026.
The ETF's outlook remains positive given its core exposure to large-cap US equities, but investors face valuation concerns with the S&P 500 trading at historically high multiples. Key risks include market volatility around inflation data and potential profit-taking near resistance levels, while institutional accumulation suggests continued confidence in the broader market trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →